What is the pathophysiology of basal cell carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathophysiology of Basal Cell Carcinoma

Basal cell carcinoma develops primarily through aberrant activation of the Hedgehog (Hh) signaling pathway, driven by loss-of-function mutations in PTCH1 (Patched-1) or gain-of-function mutations in SMO (Smoothened), with ultraviolet radiation being the principal environmental trigger for these genetic alterations 1, 2.

Molecular Mechanisms

Hedgehog Pathway Dysregulation

The core pathophysiologic mechanism centers on the Hedgehog signaling cascade:

  • PTCH1 protein normally functions as the ligand-binding component of the hedgehog receptor complex in the cell membrane, acting as a tumor suppressor
  • SMO protein transduces hedgehog signaling to downstream genes when PTCH1 inhibition is lost
  • When PTCH1 is inactivated (most commonly) or SMO is constitutively activated, uncontrolled cell proliferation occurs 1
  • Sonic hedgehog protein is the most relevant ligand in BCC pathogenesis 1

Recent evidence suggests that Hh pathway activation alone is necessary but not sufficient for BCC formation - additional genetic alterations are required to convert precursor lesions into malignant disease 3. This implies a stepwise tumor progression model rather than a single-hit mechanism.

Genetic Alterations

  • PTCH1 mutations are present in approximately 93-100% of BCCs, including those at both sun-exposed and sun-protected sites 4
  • TP53 tumor suppressor gene mutations with UV-specific nucleotide changes are commonly implicated 1
  • UV mutation signatures are characteristic of sun-exposed BCCs but notably absent in sun-protected BCCs, suggesting alternative mutagenesis mechanisms 4

Environmental and Host Factors

UV Radiation

UV-A and UV-B radiation represent the most recognized environmental carcinogens 5:

  • The relationship between sun exposure and BCC is complex, depending on timing, pattern, and cumulative amount of UV exposure
  • UV radiation causes specific nucleotide changes in PTCH1 and TP53 genes 1
  • Ionizing radiation from therapeutic sources, especially at young age, also increases BCC risk 5

Phenotypic Risk Factors

Independent risk factors related to UV susceptibility include 5:

  • Fair skin
  • Red or blond hair
  • Light eye color

Cellular Origin

BCC is thought to originate from pluripotential cells in the basal layer of the epidermis or the pilosebaceous follicle 1. There exists a well-established relationship between BCC and the pilo-sebaceous unit. Emerging evidence suggests that at least a subset of BCCs may arise from subclinical basaloid follicular hamartomas or similar precursor lesions, particularly in patients with germline PTCH1 mutations (Gorlin syndrome) 3.

Clinical Implications

Therapeutic Targeting

The central role of Hedgehog pathway dysregulation has enabled successful targeted therapy:

  • Vismodegib and sonidegib are FDA-approved SMO inhibitors that selectively block the Hedgehog pathway 6, 2, 1
  • These agents achieve objective response rates of 30-33% in metastatic BCC 6
  • The presence of upstream Hh pathway alterations even in sun-protected BCCs supports their susceptibility to these inhibitors 4

Tumor Behavior

Despite the molecular complexity, BCC has an extremely low metastatic rate (0.0028%-0.55%) but can cause substantial local destruction involving soft tissue, cartilage, and bone 6, 5. When metastasis occurs, it typically follows lymphatic spread to regional nodes followed by hematogenous dissemination to lung and bone 6.

MicroRNA Dysregulation

Emerging evidence indicates that miRNA dysregulation plays a role in BCC biology and resistance mechanisms to systemic therapies, representing a new frontier in understanding treatment resistance 7.

References

Research

Does Basal Cell Carcinoma Arise from a Precursor Lesion?

The Journal of investigative dermatology, 2025

Guideline

basal cell skin cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

guidelines of care for the management of basal cell carcinoma.

Journal of the American Academy of Dermatology, 2018

Research

Basal Cell Carcinoma: A Comprehensive Review.

International journal of molecular sciences, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.